Pipeline

Products in Development

Clarity’s theranostic programs aim to increase the probability of treatment success by selecting patients that demonstrate uptake of the diagnostic agents to visualise their cancer prior to therapy.

For indications such as prostate cancer and neuroendocrine tumours (NETs), the diagnostic products based on copper-64 (Cu-64) are also in development as stand-alone products to diagnose and manage disease in a broader spectrum of patients.